Table 4.
Risk of MACE according to various levels of lipoproteins and apo proteins in patients with STEMI
| No. at risk | Obs. years | Events | Incidence rate* | (95% CI) | Univariate analysis | Model 1 | Model 1-statin users | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio | (95% CI) | Hazard ratio† | (95% CI) | Hazard ratio# | (95% CI) | ||||||||
| Total-c, mmol/L | |||||||||||||
| High | 159 | 1113 | 55 | 4.94 | (3.72–6.43) | 0.73¯ | (0.46–1.15) | 0.73¯ | (0.45–1.18) | 0.75¯ | (0.45–1.25) | ||
| Quartile | 1 | 45 | 302 | 19 | 6.29 | (3.79–9.82) | 1 | (reference) | 1 | (reference) | 1 | (reference) | |
| 2 | 65 | 441 | 23 | 5.22 | (3.31–7.83) | 0.80¯ | (0.43–1.48) | 0.81¯ | (0.42–1.53) | 0.76¯ | (0.38–1.53) | ||
| 3 | 49 | 341 | 20 | 5.87 | (3.58–9.06) | 0.94¯ | (0.50–1.77) | 0.99¯ | (0.52–1.92) | 1.01¯ | (0.51-2.00) | ||
| 4 | 61 | 415 | 21 | 5.06 | (3.13–7.74) | 0.82¯ | (0.44–1.53) | 0.85¯ | (0.44–1.64) | 0.82¯ | (0.41–1.65) | ||
| Per SD increase | 1.10 | 0.99¯ | (0.78–1.25) | 1.02¯ | (0.79–1.30) | 1.08¯ | (0.83–1.39) | ||||||
| Triglycerides | |||||||||||||
| High | 65 | 428 | 25 | 5.84 | (3.78–8.62) | 1.10¯ | (0.69–1.75) | 1.13¯ | (0.70–1.81) | 1.11¯ | (0.68–1.83) | ||
| Quartile | 1 | 44 | 291 | 18 | 6.19 | (3.67–9.78) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 34 | 242 | 15 | 6.20 | (3.47–10.22) | 1.04¯ | (0.52–2.09) | 1.06¯ | (0.53–2.15) | 0.93¯ | (0.43–1.98) | ||
| 3 | 64 | 429 | 22 | 5.13 | (3.21–7.76) | 0.89¯ | (0.47–1.68) | 0.89¯ | (0.47–1.70) | 0.79¯ | (0.40–1.54) | ||
| 4 | 78 | 538 | 28 | 5.20 | (3.46–7.52) | 0.91¯ | (0.50–1.66) | 0.94¯ | (0.51–1.73) | 0.87¯ | (0.46–1.64) | ||
| Per ln SD increase | 0.81 | 1.01¯ | (0.97–1.04) | 1.00¯ | (0.96–1.04) | 1.00¯ | (0.96–1.04) | ||||||
| HDLc, mmol/L | |||||||||||||
| High | 159 | 1118 | 56 | 5.01 | (3.78–6.50) | 0.72¯ | (0.46–1.15) | 0.70¯ | (0.44–1.11) | 0.68¯ | (0.42–1.12) | ||
| Quartile | 1 | 72 | 462 | 30 | 6.49 | (4.38–9.27) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 50 | 378 | 14 | 3.70 | (2.02–6.21) | 0.56¯ | (0.29–1.07) | 0.56¯ | (0.29–1.08) | 0.53¯ | (0.27–1.04) | ||
| 3 | 52 | 309 | 25 | 8.09 | (5.24–11.94) | 1.21¯ | (0.71–2.06) | 1.18¯ | (0.69–2.02) | 1.09¯ | (0.61–1.93) | ||
| 4 | 46 | 350 | 14 | 4.00 | (2.19–6.71) | 0.66¯ | (0.35–1.24) | 0.57¯ | (0.29–1.14) | 0.60¯ | (0.29–1.23) | ||
| Per SD increase | 0.40 | 0.95¯ | (0.75–1.22) | 0.92¯ | (0.71–1.20) | 0.94¯ | (0.71–1.24) | ||||||
| LDLc, mmol/L | |||||||||||||
| High | 156 | 57 | 1083 | 5.26 | (3.99–6.92) | 0.83¯ | (0.52–1.33) | 0.90¯ | (0.54–1.48) | 0.84¯ | (0.50–1.41) | ||
| Quartile | 1 | 72 | 295 | 21 | 7.12 | (4.41–10.88) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 50 | 414 | 20 | 4.83 | (2.95–7.46) | 0.68¯ | (0.37–1.26) | 0.76¯ | (0.40–1.45) | 0.65¯ | (0.33–1.28) | ||
| 3 | 52 | 491 | 24 | 4.89 | (3.13–7.27) | 0.65¯ | (0.36–1.18) | 0.69¯ | (0.37–1.30) | 0.64¯ | (0.34–1.23) | ||
| 4 | 46 | 300 | 18 | 6.00 | (3.56–9.48) | 0.81¯ | (0.43–1.52) | 0.89¯ | (0.46–1.73) | 0.77¯ | (0.39–1.54) | ||
| Per SD increase | 1.00 | 0.96¯ | (0.75–1.22) | 0.99¯ | (0.76–1.28) | 0.92¯ | (0.75–1.29) | ||||||
| Remnant cholesterol, mmol/L | |||||||||||||
| High | 75 (34) | 507 | 28 | 5.53 | (3.67–7.98) | 1.02¯ | (0.65–1.61) | 1.05 | (0.66–1.66) | 1.07¯ | (0.66–1.73) | ||
| 1 | 44 (20) | 291 | 18 | 6.19 | (3.67–9.78) | 1 | (reference) | 1 | (reference) | 1 | (reference) | ||
| 2 | 33 (15) | 232 | 15 | 6.47 | (3.62–10.66) | 1.08¯ | (0.54-.2.17) | 1.11¯ | (0.55–2.25) | 0.92¯ | (0.43–1.98) | ||
| 3 | 63 (29) | 419 | 22 | 9.48 | (5.94–14.38) | 0.91¯ | (0.48–1.72) | 0.91¯ | (0.48–1.74) | 0.80¯ | (0.41–1.57) | ||
| 4 | 80 (36) | 557 | 28 | 5.03 | (3.34–7.27) | 0.88¯ | (0.48–1.60) | 0.91¯ | (0.49–1.67) | 0.86¯ | (0.46–1.61) | ||
| Per SD increase | 0.36 | 1.06¯ | (0.95–1.19) | 1.04¯ | (0.93–1.16) | 1.07¯ | (0.94–1.21) | ||||||
| Apo A1, g/L | |||||||||||||
| High | 96 | 651 | 36 | 5.53 | (3.87–7.66) | 1.05¯ | (0.68–1.63) | 1.01¯ | (0.63–1.61) | 0.93¯ | (0.56–1.55) | ||
| Quartile | 1 | 153 | 1034 | 61 | 5.60 | (4.51–7.58) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 30 | 165 | 13 | 7.88 | (4.20-13.47) | 1.36¯ | (0.74–2.47) | 1.25¯ | (0.67–2.36) | 1.11¯ | (0.54–2.27) | ||
| 3 | 28 | 235 | 6 | 2.55 | (0.94–5.56) | 0.48¯ | (0.21–1.11) | 0.42¯ | (0.18–1.02) | 0.44¯ | (0.18–1.06) | ||
| 4 | 9 | 65 | 3 | 4.62 | (0.95–13.49) | 0.82¯ | (0.29–2.63) | 0.70¯ | (0.21–2.30) | 0.82¯ | (0.25–2.72) | ||
| Per SD increase | 0.31 | 0.84¯ | (0.63–1.13) | 0.80¯ | (0.59–1.10) | 0.78¯ | (0.56–1.09) | ||||||
| Apo B, g/L | |||||||||||||
| High | 172 | 1176 | 60 | 5.10 | (3.89–6.57) | 0.71¯ | (0.44–1.16) | 0.77¯ | (0.46–1.31) | 0.67¯ | (0.40–1.15) | ||
| Quartile | 1 | 17 | 116 | 7 | 6.03 | (2.43–12.43) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 43 | 275 | 21 | 7.64 | (4.73–11.67) | 1.17 ¯ | (0.50–2.78) | 1.24¯ | (0.48–3.19) | 0.97¯ | (0.33–2.90) | ||
| 3 | 74 | 537 | 24 | 4.47 | (2.86–6.65) | 0.75¯ | (0.32–1.73) | 0.84¯ | (0.33–2.15) | 0.64¯ | (0.22–1.87) | ||
| 4 | 86 | 571 | 31 | 5.43 | (3.69–7.71) | 0.89¯ | (0.39–2.02) | 0.99¯ | (0.39–2.53) | 0.78¯ | (0.27–2.23) | ||
| Per SD increase | 0.29 | 0.91¯ | (0.70–1.19) | 0.94¯ | (0.71–1.25) | 0.93¯ | (0.69–1.25) | ||||||
| Apo C-I, mg/L | |||||||||||||
| Quartile | 1 | 85 | 544 | 37 | 6.80 | (4.79–9.37) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 54 | 406 | 17 | 4.19 | (2.44–6.70) | 0.65¯ | (0.37–1.16) | 0.66¯ | (0.37–1.18) | 0.64¯ | (0.34–1.20) | ||
| 3 | 44 | 294 | 17 | 5.78 | (3.37–9.26) | 0.91¯ | (0.51–1.61) | 0.89¯ | (0.49–1.62) | 0.86¯ | (0.48–1.60) | ||
| 4 | 37 | 256 | 12 | 4.69 | (2.42–8.19) | 0.73¯ | (0.38–1.40) | 0.76¯ | (0.39–1.50) | 0.73¯ | (0.37–1.49) | ||
| Per SD increase | 5.33 | 1.03¯ | (0.86–1.22) | 1.04¯ | (0.88–1.22) | 1.04¯ | (0.88–1.23) | ||||||
| Apo C-II, mg/L | |||||||||||||
| Quartile | 1 | 47 | 322 | 19 | 5.90 | (3.55–9.21) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 58 | 379 | 26 | 6.86 | (4.48–10.05) | 1.32¯ | (0.68–2.25) | 1.34¯ | (0.72–2.49) | 1.46¯ | (0.75–2.86) | ||
| 3 | 52 | 375 | 16 | 4.27 | (2.44–6.93) | 0.78¯ | (0.40–1.52) | 0.83¯ | (0.42–1.64) | 0.89¯ | (0.43–1.85) | ||
| 4 | 63 | 423 | 22 | 5.20 | (3.26–7.87) | 0.96¯ | (0.51–1.78) | 0.98¯ | (0.51–1.86) | 1.05¯ | (0.52–2.12) | ||
| Per ln SD increase | 27.64 | 1.01¯ | (0.99–1.02) | 1.01¯ | (0.99–1.02) | 1.01¯ | (0.99–1.02) | ||||||
| Apo C-III, mg/L | |||||||||||||
| Quartile | 1 | 81 | 509 | 37 | 7.27 | (5.12–10.02) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 51 | 392 | 14 | 3.57 | (1.95–5.99) | 0.55 ¯ | (0.30–1.02) | 0.55¯ | (0.30–1.02) | 0.53¯ | (0.27–1.03) | ||
| 3 | 40 | 281 | 15 | 5.34 | (2.99–8.80) | 0.79¯ | (0.43–1.44) | 0.81¯ | (0.44–1.50) | 0.75¯ | (0.39–1.42) | ||
| 4 | 48 | 317 | 17 | 5.36 | (3.12–8.59) | 0.81¯ | (0.45–1.44) | 0.79¯ | (0.43–1.44) | 0.77¯ | (0.41–1.44) | ||
| Per SD increase | 37.12 | 1.01¯ | (1.00-1.02) | 1.01¯ | (1.00-1.02) | 1.01¯ | (1.00-1.02) | ||||||
| Apo E, mg/L | |||||||||||||
| Quartile | 1 | 45 | 309 | 18 | 5.83 | (3.45–9.21) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 61 | 367 | 28 | 7.63 | (5.07–11.03) | 1.33¯ | (0.73–2.44) | 1.49¯ | (0.78–2.86) | 1.28¯ | (0.65–2.53) | ||
| 3 | 62 | 479 | 18 | 3.76 | (2.23–5.94) | 0.70¯ | (0.36–1.36) | 0.75¯ | (0.38–1.49) | 0.81¯ | (0.39–1.66) | ||
| 4 | 52 | 344 | 19 | 5.52 | (3.33–8.63) | 0.99¯ | (0.51–1.90) | 1.13¯ | (0.57–2.26) | 0.96¯ | (0.46–1.99) | ||
| Per SD increase | 13.04 | 1.07¯ | (0.98–1.16) | 1.07¯ | (0.99–1.16) | 1.07¯ | (0.99–1.16) | ||||||
| Ratio ApoB/ApoA1 | |||||||||||||
| Quartile | 1 | 5 | 28 | 4 | 1.14 | (0.31–2.93) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 27 | 186 | 10 | 5.38 | (2.58–9.89) | 0.44¯ | (0.14–1.40) | 0.43¯ | (0.13–1.41) | 0.55¯ | (0.15–2.01) | ||
| 3 | 50 | 337 | 20 | 5.93 | (3.63–9.17) | 0.46¯ | (0.16–1.36) | 0.43¯ | (0.15–1.33) | 0.41¯ | (0.12–1.44) | ||
| 4 | 138 | 948 | 49 | 5.17 | (3.82–6.83) | 0.40¯ | (0.14–1.11) | 0.41¯ | (0.14–1.18) | 0.45¯ | (0.14–1.48) | ||
| Per SD increase | 0.25 | 1.05¯ | (0.86–1.27) | 1.08¯ | (0.88–1.33) | 1.07¯ | (0.86–1.32) | ||||||
| Non-HDLc, mmol/L | |||||||||||||
| Quartile | 1 | 33 | 207 | 15 | 7.25 | (4.01–11.95) | 1 | (references) | 1 | (reference) | 1 | (reference) | |
| 2 | 47 | 341 | 17 | 4.99 | (2.90–7.98) | 0.68¯ | (0.34–1.38) | 0.70¯ | (0.32–1.51) | 0.53¯ | (0.23–1.12) | ||
| 3 | 85 | 601 | 29 | 4.86 | (3.23–6.93) | 0.68¯ | (0.36–1.27) | 0.71¯ | (0.37–1.39) | 0.65¯ | (0.32–1.32) | ||
| 4 | 55 | 350 | 22 | 6.29 | (3.94–9.52) | 0.87¯ | (0.45–1.68) | 0.92¯ | (0.45–1.89) | 0.78¯ | (0.38–1.62) | ||
| Per SD increase | 1.13 | 1.00¯ | (0.78–1.28) | 1.05¯ | (0.81–1.35) | 1.05¯ | (0.81–1.37) | ||||||
Significance: ¯p > 0.05
*Model 1; Adjusted for age, sex and statin use
†Model 1-statin users; Adjusted for age and sex, statin users excluded